If you are dealing with a tendon that has not settled down after four months, or a shoulder that flares every time you go back to training, you have probably run into the same two names within ten minutes of searching: BPC-157 and TB-500. They get mentioned in the same breath, bundled into the same blends, and described in nearly interchangeable language. That makes it easy to assume they are two brands of the same idea.
They are not. They come from different tissues, they are different sizes, and the laboratory work behind them points at different steps of the repair process. One is a fifteen-amino-acid fragment first identified in human gastric juice, studied mostly around blood vessels, tendon cells and the gut lining. The other is a synthetic piece of a protein that sits inside almost every cell in your body and controls how cells physically move.
Understanding that difference is genuinely useful, because it is the thing a prescribing clinician will reason about when deciding whether either one belongs in your plan. But there is a limit worth stating before anything else: for both compounds, the overwhelming majority of the published evidence comes from animals and cell cultures. Three small human pilot studies exist for BPC-157. Neither compound is approved by the FDA for any indication. Anyone selling you certainty here is selling you something the literature does not contain.
Here is the honest head-to-head.
What BPC-157 is
BPC-157 stands for Body Protection Compound-157. It is a synthetic peptide fifteen amino acids long, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular weight of 1,419.53 daltons. The sequence derives from a protein found in human gastric juice, which is also where its research history begins: it was first characterized for gastroprotective effects, with animal studies examining whether it protected the stomach lining against damage from NSAIDs, alcohol and stress-induced lesions.
Preclinical work has run since the early 1990s. A 2025 systematic review in HSS Journal screened 544 articles and included 36 spanning more than three decades of literature, from 1993 to 2024. Of those 36 studies, 35 were preclinical and one was clinical. Within that preclinical body, the review reported improved functional, structural and biomechanical outcomes across four injury categories: muscle, tendon, ligament and bone. That is a real finding about animal models, and it should be read as exactly that.
The mechanisms, in detail
The nitric oxide axis. A 2020 study in Scientific Reports traced BPC-157's effect on vasomotor tone through the Src–Caveolin-1–eNOS pathway. In isolated rat aorta, BPC-157 produced concentration-dependent vasodilation that depended on an intact endothelium and disappeared when the researchers added L-NAME or hemoglobin, both of which block or mop up nitric oxide. The compound increased phosphorylation of Src, Caveolin-1 and endothelial nitric oxide synthase, and that increase was abolished by a Src inhibitor. Mechanistically, the interesting step is that BPC-157 reduced the binding between Caveolin-1 and eNOS — Caveolin-1 normally holds eNOS in an inactive state, so loosening that grip is what frees the enzyme to produce nitric oxide. The resulting nitric oxide is central to endothelial function and to angiogenesis, the growth of new blood vessels, and the same paper showed it promoted migration of vascular endothelial cells.
The growth factor axis. A 2014 study in Molecules, working with tendon fibroblasts taken from the Achilles tendons of male Sprague-Dawley rats, found that BPC-157 increased expression of the growth hormone receptor. The finding came out of a cDNA microarray in which the receptor was among the most abundantly upregulated genes, and the increase was both dose- and time-dependent at the mRNA and protein level. When the researchers added growth hormone to BPC-157-treated fibroblasts, cell proliferation increased, and JAK2 — the signaling molecule downstream of the growth hormone receptor — was activated in a time-dependent way. The authors framed this as a mechanism through which the peptide may support tissue remodeling.
The cell migration axis. A 2011 study in the Journal of Applied Physiology looked at tendon healing directly. BPC-157 accelerated outgrowth from tendon explants, increased cell survival specifically under hydrogen peroxide oxidative stress, and enhanced tendon fibroblast migration in a dose-dependent manner in a transwell assay. It did not increase proliferation on its own. It induced F-actin formation and produced dose-dependent phosphorylation of FAK and paxillin, leading the authors to conclude the effect was likely mediated by the FAK–paxillin pathway. Separately, a 2003 study in the Journal of Orthopaedic Research reported accelerated healing of transected Achilles tendons in rats, and stimulated tendocyte growth in vitro.
Breadth beyond musculoskeletal tissue. A 2024 review in Pharmaceuticals documented what it called pleiotropic activity across neurotransmitter systems, describing counteraction of disturbances in dopamine, serotonin, glutamate, GABA, adrenaline and noradrenaline, acetylcholine and the nitric oxide system, along with activation of VEGF and growth hormone receptors and effects on nerve–muscle relationships. A 2025 review in Current Reviews in Musculoskeletal Medicine adds VEGFR2, the Akt–eNOS axis and ERK1/2 signaling to the mechanistic picture, and notes that the described effects concentrate in poorly vascularized tissue such as tendon and the myotendinous junction — which, if it holds up, would be an argument for why the tendon literature is the densest part of the file.
The human evidence
This is the part that gets skipped in most comparisons. The same 2025 review in Current Reviews in Musculoskeletal Medicine that called the preclinical data extensive also counted the human data precisely: three pilot studies. One examined intraarticular injection for knee pain, one interstitial cystitis, and one intravenous safety and pharmacokinetics. No adverse effects were reported in them. Three small pilots is a starting point for research, not a substitute for controlled trials. That same review also notes BPC-157's prohibited status in professional sport, which matters if you compete under any anti-doping code.
A fuller standalone review of the BPC-157 literature — mechanisms, regulatory record, and what a compounded prescription changes — is in our BPC-157 peptide therapy article.
What TB-500 is
TB-500 is a synthetic peptide based on the active region of thymosin beta-4, usually written Tβ4. Thymosin beta-4 is a 43-amino-acid protein, first isolated from the thymus gland, and found naturally in nearly all mammalian cells. That origin story is a clean contrast with BPC-157: one comes from a gastric sequence, the other from a protein your cells already make constantly.
A correction worth making
You will see it stated across the internet that TB-500's active sequence is Ac-SDKP, amino acids 17–23. That sentence fuses two different molecules.
Residues 17–23 of thymosin beta-4 are LKKTETQ. That is the actin-binding motif, and it is the region TB-500 is built around. Ac-SDKP — N-acetyl-Ser-Asp-Lys-Pro — is a separate tetrapeptide from the opposite end of the protein, residues 1–4, and it has its own research literature that is largely about fibrosis. Both fragments are real and both are studied. They are not the same fragment, and repeating the merged version tells you the writer copied it from somewhere else.
The list of bioactivities usually attached to the active region — cell migration, angiogenesis and anti-inflammatory effects — is standard and supportable. The residue numbering that often travels with it is not.
A second distinction that matters more than it sounds
Almost every impressive number attached to "TB-500" in popular articles was generated with thymosin beta-4 itself, not with the synthetic fragment. The wound-healing work, the cardiac work, the clinical programs: all thymosin beta-4. TB-500 is a synthetic analogue of part of that protein.
That does not make the parent research irrelevant — it is the reason anyone is interested in the fragment at all. But a fragment is not the whole molecule, and evidence generated with one does not automatically transfer to the other. Where the studies below used Tβ4, this article says Tβ4.
The mechanisms, in detail
Actin sequestration. A 2021 review in Frontiers in Endocrinology describes thymosin beta-4's primary molecular role as regulating actin, the structural protein inside cells, and classifies it as an actin-sequestering protein. It binds G-actin monomers in a 1:1 ratio, which maintains a pool of unpolymerized actin that can be rapidly mobilized when the cell needs to rebuild its internal scaffolding. That remodeling is what allows a cell to physically move, and cell migration underlies wound healing, angiogenesis and tissue regeneration. The same review documents these pathways across multiple tissue types. It is a genuinely different kind of mechanism from BPC-157's — a structural one, operating inside the cell, rather than a signaling one operating on receptors and vessel tone.
Wound healing. The one place this literature produces hard numbers is a 1999 study in the Journal of Investigative Dermatology. In a rat full-thickness wound model, thymosin beta-4 applied topically or intraperitoneally increased re-epithelialization — the resurfacing of the wound with new skin cells — by 42% at four days and by up to 61% at seven days compared with saline controls. Wounds also contracted at least 11% more than controls by day seven, with increased collagen deposition and angiogenesis. In a Boyden chamber assay, Tβ4 stimulated keratinocyte migration two- to three-fold over medium alone within four to five hours, with as little as 10 picograms.
Those percentages circulate widely without the words "rat" or "full-thickness wound" attached to them. They belong there. This was a topical and injected wound model in rodents, not a study of a human tendon injury.
Angiogenesis. A 2004 paper in Mechanisms of Ageing and Development reported that thymosin beta-4 promoted angiogenesis and wound healing in both normal and aged rodent models, by upregulating VEGF expression. The aged-animal arm is worth noting, since impaired healing with age is one of the reasons people start looking into any of this.
Cardiac work. Two papers in Annals of the New York Academy of Sciences, from 2007 and 2010, describe thymosin beta-4 as initiating myocardial and vascular regeneration after systemic administration in animals — the 2010 paper's own phrasing is the first known molecule to do so in vivo, which is a claim about the animal literature, not about people. Mechanistically, Tβ4 forms a functional complex with PINCH and integrin-linked kinase, which activates the survival kinase Akt. After coronary artery ligation in mice, treatment upregulated ILK and Akt activity, improved early myocyte survival and improved cardiac function. Reported effects include reduced cell death and activation of endogenous cardiac progenitor cells, plus epicardial thickening and a progenitor increase that occurred independent of injury.
Clinical progress — for the parent protein. A 2012 review in Expert Opinion on Biological Therapy describes thymosin beta-4 as released by platelets and macrophages after injury, reducing apoptosis and inflammation, mobilizing and differentiating stem and progenitor cells, and decreasing myofibroblast numbers, which the authors link to less scarring and fibrosis. It documents clinical programs including corneal repair trials, along with dermal wounds, cardiac and central nervous system applications following ischemic insult and trauma. Thymosin beta-4 has therefore progressed to clinical evaluation in a way BPC-157 has not — and it still holds no regulatory approval for any indication.
Head-to-head
| Dimension | BPC-157 | TB-500 |
|---|---|---|
| Identity | Body Protection Compound-157; synthetic pentadecapeptide | Synthetic peptide based on the active region of thymosin beta-4 |
| Biological origin | Sequence found in human gastric juice | Parent protein first isolated from the thymus; present in nearly all mammalian cells |
| Length | 15 amino acids | Parent Tβ4 is 43 amino acids; TB-500 is a fragment of it |
| Active region | The full 15-mer | Built around LKKTETQ, residues 17–23 (not Ac-SDKP, residues 1–4) |
| Molecular weight | 1,419.53 Da | Full-length Tβ4 is roughly 4,900 Da |
| Central mechanism | Nitric oxide modulation, growth factor receptor upregulation, cytoprotection | Actin sequestration: 1:1 G-actin binding, cytoskeletal remodeling |
| Named pathway | Src → Caveolin-1 → eNOS → nitric oxide; FAK–paxillin | G-actin binding → cytoskeletal remodeling → cell migration; VEGF upregulation |
| Growth factor link | Upregulates growth hormone receptor in tendon fibroblasts | Upregulates VEGF |
| Where it acts | Described as primarily local, concentrating at sites of damage | Described as more systemic, across multiple tissue types |
| Flagship soft-tissue data | Tendon explant outgrowth, survival under oxidative stress, dose-dependent fibroblast migration; transected rat Achilles healing | Re-epithelialization +42% at day 4, up to +61% at day 7 in a rat full-thickness wound model |
| Gastrointestinal data | Yes — original characterization, animal models | None in this literature |
| Cardiac data | None in this literature | Yes — as Tβ4, in mouse models |
| Angiogenesis route | Nitric oxide, downstream of eNOS | VEGF upregulation plus cell migration |
| Stability | Described as unusually stable in gastric juice and aqueous solution | No stability claim in these reviews |
| Half-life | Reported at under 30 minutes, hepatic metabolism, renal clearance | Often described as longer; no figure in these reviews |
| Human data | Three pilot studies | None for the fragment; parent protein has reached clinical evaluation |
| Regulatory status | Not FDA-approved for any indication | Not FDA-approved for any indication |
Origin and size
BPC-157 is roughly three and a half times lighter than full-length thymosin beta-4 — 1,419.53 daltons against about 4,900. It is frequently claimed that this size difference drives differences in tissue distribution and stability. That is a plausible hypothesis and it is not a finding; none of the papers here tested it. Treat it as a reasonable guess that nobody has closed out.
Mechanism: two different bottlenecks
This is the most useful contrast in the comparison. Tissue repair has multiple rate-limiting steps: blood supply to the area, cell survival in a hostile local environment, cells arriving where they are needed, and cells reorganizing once there.
The BPC-157 literature clusters on the first two. Nitric oxide signaling and vessel tone, endothelial cell migration, survival under oxidative stress, growth hormone receptor expression on the fibroblasts that build tendon.
The thymosin beta-4 literature clusters on the second two. Actin sequestration is a machinery-level mechanism for cell motility, and the wound-healing, angiogenesis and cardiac findings all read as consequences of cells moving and rebuilding structure.
Local versus systemic
The standard framing is that BPC-157 acts primarily at injury sites while TB-500 acts more systemically. It is a fair summary of where each has been studied and what each mechanism implies. It is not a measured head-to-head comparison — no published study put both compounds through the same distribution protocol. Read the local/systemic split as a description of two research programs, not as a biodistribution result.
Depth of evidence
Both compounds have been studied for over two decades. The depth is not equal, and it is not equal in the way most articles imply.
BPC-157 has the deeper dedicated preclinical file: 36 studies in the 2025 systematic review, three decades of animal work, several well-characterized pathways. It has three human pilots.
TB-500 as a distinct molecule has a thinner file. Its parent, thymosin beta-4, has gone furthest into clinical evaluation, including corneal repair. So "TB-500 has more clinical evidence" is not quite right — thymosin beta-4 does, and TB-500 is a fragment of it.
Stability and half-life
There is a real distinction here, and it is regularly muddled. BPC-157 is described as unusually stable in gastric juice and aqueous solution, which is a statement about resisting degradation, and it is unusual among peptides. It is not the same as a long half-life: the 2025 systematic review reports a half-life under 30 minutes, with hepatic metabolism and renal clearance.
TB-500 is widely said to have a longer half-life. None of the reviews cited here supplies a number for it. A comparison that cannot state a value on one side is not a comparison, and you should treat any confident half-life figure for TB-500 as unsourced until someone shows you the paper.
Gaps that are just gaps
The comparison is asymmetric in two places worth flagging. There is gastrointestinal evidence for BPC-157 and none for TB-500. There is cardiac evidence for thymosin beta-4 and none for BPC-157. Neither absence means the compound was tried and failed. It means nobody in this literature ran the study. Absence of evidence and evidence of absence look identical in a comparison table, and they are not the same thing.
What about using both?
The mechanistic argument for combining them is easy to state: if BPC-157's studied contribution is local vascular support and cytoprotection, and thymosin beta-4's is systemic cell migration and structural reorganization, then they address different bottlenecks and might not overlap.
Here is the part that usually goes missing. No study cited in this literature tested the two compounds together. The combination case is inference drawn from two separate single-compound reviews — the 2024 Pharmaceuticals review of BPC-157 and the 2021 Frontiers in Endocrinology review of thymosin beta-4. Neither one investigated a combination. The reasoning is mechanistic, and mechanistic reasoning is how research questions get generated, not how they get answered.
That does not make a combination unreasonable. It makes it untested. Anyone presenting synergy as a demonstrated result is describing an argument, not data, and a clinician evaluating a combination is weighing that same argument with no combination trial to lean on.
The pairing is common enough to have a nickname — we cover the Wolverine peptide stack, including this same untested-combination caveat, in its own article.
What the research still does not tell us
A 2019 paper in Cell Tissue Research is the clearest statement of the limits. It found that while preclinical models consistently show positive outcomes, translation to human applications requires large-scale controlled clinical trials that have not been completed. It also notes that the majority of studies are small rodent models, with few adverse reactions reported.
The specific things nobody can currently tell you:
- Whether the preclinical results translate. Most compounds that look good in rodents do not survive human trials. That is the base rate, not pessimism.
- Which one is better for your injury. No study has compared them head to head in humans, or in animals. The comparison in this article is between two separate literatures.
- Long-term safety in humans. Three pilot studies with no adverse effects reported is reassuring at the scale of three pilot studies.
- Whether combining them adds anything. Untested, as above.
- Regulatory standing. Neither BPC-157 nor TB-500 is approved by the FDA for any indication. When either is dispensed through this platform, it is a compounded preparation made by a licensed compounding pharmacy on a prescription — compounded medications are not FDA-approved products, and no claim otherwise is being made here.
How this decision actually gets made
The comparison above will not tell you which peptide is right for you, and it is not supposed to. What it should do is make you a better participant in the conversation where that gets decided.
Every request through Promise is reviewed by a licensed provider in our prescriber network. They look at your history, your injury, your medications, and what you are actually trying to accomplish. Not everyone qualifies. A provider can decline, and does — including when the honest answer is that the evidence for what you are asking about is thin, or when something else should be ruled out first. Anything prescribed is a compounded preparation, dispensed by a licensed compounding pharmacy, not an over-the-counter product and not a research chemical bought from an unregulated seller.
Useful things to bring to that visit: what happened and when, what you have already tried, imaging if you have it, everything else you take, and whether you compete under an anti-doping code.
Details of the compounded preparations themselves are on the BPC-157 and TB-500 product pages.
Sources
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025 Nov;21(4):485-495. PubMed
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-80. PubMed
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976-83. PubMed
- Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports. 2020;10(1):17078. PubMed
- Chang CH, et al. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(11):19066-19077. PubMed
- Sikiric P, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals. 2024;17(4):461. PubMed
- McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025 Dec;18(12):611-619. PubMed
- Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019;377(2):153-159. PubMed
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-8. PubMed
- Philp D, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of Ageing and Development. 2004;125(2):113-5. PubMed
- Srivastava D, et al. Thymosin beta4 is cardioprotective after myocardial infarction. Annals of the New York Academy of Sciences. 2007;1112:161-70. PubMed
- Shrivastava S, et al. Thymosin beta4 and cardiac repair. Annals of the New York Academy of Sciences. 2010;1194:87-96. PubMed
- Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51. PubMed
- Xing Y, et al. Progress on the Function and Application of Thymosin β4. Frontiers in Endocrinology. 2021;12:767785. PubMed
This article is for general education and is not medical advice. It does not diagnose any condition, and nothing in it should be used to start, stop or change a treatment. Study results described here occurred in the populations those studies enrolled — most often rodents and cell cultures — and no outcome is guaranteed for any individual. Talk to a licensed provider about your own situation.